Aggregation of human plasma and of human blood induced in vitro by pegfilgrastim originator formulation buffer and pegfilgrastim products

Critical Influences of Plasma pH on Human Protein Properties for Modeling Considerations: Size, Charge, Conformation, Hydrophobicity, and Denaturation

(2023) Majak Mapiour et al.   Journal of Composites Science

The ELISA Detectability and Potency of Pegfilgrastim Decrease in Physiological Conditions: Key Roles for Aggregation and Individual Variability

(2020) Tao Xie et al.   Scientific Reports

Defining the right diluent for intravenous infusion of therapeutic antibodies

(2019) Shen Luo et al.   mAbs

Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor

(2015) Tara Arvedson et al.   BIODRUGS

Dextrose-mediated aggregation of therapeutic monoclonal antibodies in human plasma: Implication of isoelectric precipitation of complement proteins

(2015) Shen Luo et al.   mAbs

Kinetic analysis of thermal stability of human low density lipoproteins: a model for LDL fusion in atherogenesis

(2012) Mengxiao Lu et al.   JOURNAL OF LIPID RESEARCH

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

(2008) Jorge Sierra et al.   BMC CANCER

Formulation of Neulasta® (pegfilgrastim)

(2007) Deirdre Murphy Piedmonte et al.   ADVANCED DRUG DELIVERY REVIEWS